Relation of Beta-Blocker-Induced Heart Rate Lowering and Cardioprotection in Hypertension

Department of Medicine, Division of Cardiology, St Luke's Roosevelt Hospital, Columbia University College of Physicians and Surgeons, New York, New York 10019, USA.
Journal of the American College of Cardiology (Impact Factor: 15.34). 10/2008; 52(18):1482-9. DOI: 10.1016/j.jacc.2008.06.048
Source: PubMed

ABSTRACT The purpose of this study was to evaluate the role of heart rate reduction with beta-blockers on the risk of cardiovascular events in patients with hypertension.
Resting heart rate has been shown to be a risk factor for cardiovascular morbidity and mortality in the general population and in patients with heart disease such as hypertension, myocardial infarction, and heart failure. Conversely, pharmacological reduction of heart rate is beneficial for patients with heart disease. However, the role of pharmacological reduction of heart rate using beta-blockers in preventing cardiovascular events in patients with hypertension is not known.
We conducted a MEDLINE/EMBASE/CENTRAL database search of studies from 1966 to May 2008. We included randomized controlled trials that evaluated beta-blockers as first-line therapy for hypertension with follow-up for at least 1 year and with data on heart rate. We extracted the baseline characteristics, the blood pressure response, heart rate at the baseline and end of trial, and cardiovascular outcomes from each trial.
Of 22 randomized controlled trials evaluating beta-blockers for hypertension, 9 studies reported heart rate data. The 9 studies evaluated 34,096 patients taking beta-blockers against 30,139 patients taking other antihypertensive agents and 3,987 patients receiving placebo. Paradoxically, a lower heart rate (as attained in the beta-blocker group at study end) was associated with a greater risk for the end points of all-cause mortality (r = -0.51; p < 0.0001), cardiovascular mortality (r = -0.61; p < 0.0001), myocardial infarction (r = -0.85; p < 0.0001), stroke (r = -0.20; p = 0.06), or heart failure (r = -0.64; p < 0.0001). The same was true when the heart rate difference between the 2 treatment modalities at the end of the study was compared with the relative risk reduction for cardiovascular events.
In contrast to patients with myocardial infarction and heart failure, beta-blocker-associated reduction in heart rate increased the risk of cardiovascular events and death for hypertensive patients.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The linear relationship between blood pressure (BP) and heart rate (or period) over 24 h has been suggested to be a marker for neural regulation of the circadian variations in BP and heart rate. We investigated the predictive power of indices defined by the ratio between BP and heart period variability that is a known expression for such a relationship. We analysed BP and heart rate data obtained by standard 24-h BP monitoring in 1246 hypertensive patients, 76 of whom died from all causes during 5-year follow-up. SBP, DBP and heart period (T) variabilities were estimated by standard deviations. Studied indices were the SBP-T variability ratio (dS/dT) and the DBP-T variability ratio (dD/dT). Standardized hazard ratios and odds ratios were determined using Cox regression and logistic regression, respectively. Significant covariates adjusted hazard ratios for dS/dT and dD/dT that gradually increased across the following cohorts: entire sample, high-median age and high-median age and heart period: mean [95% confidence interval (95% CI)] 1.23 (1.03-1.47), 1.26 (1.05-1.52) and 1.55 (1.19-2.02), and 1.36 (1.07-1.72), 1.40 (1.09-1.80) and 1.57 (1.15-2.14), respectively. The corresponding odd ratios were similar in all cohorts: about 1.5 (1.2-2.0) and 1.3 (1.1-1.5). The adjusted indices size was greater in nonsurvivors (P =0.000001 and P = 0.003, respectively). The 24-h BP to heart period variability ratios are powerful independent predictors of all-cause mortality, especially for elderly hypertensive patients with slow heart rate. The results support their interpretation as integrative indices of cardiovascular function and markers for cardiovascular dysregulation during low DBP states, with potential use in clinical practice.
    Journal of Hypertension 03/2015; 33(3):491-8. DOI:10.1097/HJH.0000000000000459 · 4.22 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: It has been almost 5 years since the publication of the 2010 hypertension guidelines of the Taiwan Society of Cardiology (TSOC). There is new evidence regarding the management of hypertension, including randomized controlled trials, non-randomized trials, post-hoc analyses, subgroup analyses, retrospective studies, cohort studies, and registries. More recently, the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) published joint hypertension guidelines in 2013. The panel members who were appointed to the Eighth Joint National Committee (JNC) also published the 2014 JNC report. Blood pressure (BP) targets have been changed; in particular, such targets have been loosened in high risk patients. The Executive Board members of TSOC and the Taiwan Hypertension Society (THS) aimed to review updated information about the management of hypertension to publish an updated hypertension guideline in Taiwan.
    Journal of the Chinese Medical Association 12/2014; 78(1). DOI:10.1016/j.jcma.2014.11.005 · 0.89 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The treatment of migraine depends on the frequency, severity and concomitant diseases. There are several specific drugs developed for migraine prevention in addition to the additive antimigraine effects of some other non-specific drugs. The aim of this literature-based review is to summarize the possible antimigraine properties of different antihypertensive agents (beta-blockers, calcium channel blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, etc.) focusing on the possible side effects (avoidance of beta blockers in the absence of heart disease, possible antiparkinson effect of calcium channel blockers, additive effect of drugs modifying the renin-angiotensin system activity, etc.). Current evidence supports the use of angiotensin converting enzyme inhibitors (mainly lisinopril) and angiotensin receptor blockers (mainly candesartan) for long-term migraine prevention and blood pressure control. Long-term beta-blocker treatment should be avoided in the absence of ischemic heart disease due to possible unfavourable cardiovascular effects. Orv. Hetil., 2015, 156(5), 179-185.
    Orvosi Hetilap 02/2015; 156(5):179-185. DOI:10.1556/OH.2015.30056

Full-text (2 Sources)

Available from
May 30, 2014